It seems that Serono is likely to be acquired by big pharma as Serono’s strategic growth has been slow which reflected by its share price. Potential suitors including Novartis, Roche Holding, GlaxoSmithKline, Sanofi-aventis, Johnson & Johnson and Pfizer would make their bids for Serono in a deal worth up to US$15 B. The analyst opinion article states that acquiring Serono would be advantageous to big pharma that includes acquiring a branded company which has global manufacturing capabilities and a strong foothold in the area of multiple sclerosis.